Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US9249397B2 · kind B2 · utility
2Cited by
2References
17Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 27, 2015 |
| Grant date | Feb 2, 2016 |
| Priority date | — |
| Expiry date | Jul 27, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y301/06013
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are a composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for treating Hunter syndrome. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.